Form 4: Elevance Health EVP Acquires Shares, Options

Elevance Health's EVP & Chief Legal Officer, Erin M. Wessling, reported acquiring restricted stock units and stock options, alongside a disposition of shares for tax purposes.

Summary

• EVP & Chief Legal Officer Erin M. Wessling acquired 2,976 restricted share units of Elevance Health, Inc. common stock on March 2, 2026, at a price of $0.
• These restricted share units will vest in three equal annual installments of 992 shares each, beginning on March 2, 2027.
• Wessling also acquired 11,754 employee stock options on March 2, 2026, with an exercise price of $294.07.
• These options are exercisable in three annual installments of 3,918 shares each, starting on March 2, 2027, and will expire on March 2, 2036.
• On March 3, 2026, Wessling disposed of 417 shares of common stock at a price of $284.03 to cover tax liabilities related to the vesting of previously granted restricted stock.
• Following these transactions, Wessling beneficially owns 7,579 shares of common stock and 11,754 employee stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting routine executive compensation and an increase in insider equity holdings, which generally aligns management interests with long-term shareholder value.

Positives

• EVP & Chief Legal Officer Erin M. Wessling acquired 2,976 restricted share units, indicating continued alignment of management interests with shareholder value.
• The grant of 11,754 employee stock options further incentivizes long-term performance and retention of key executive talent.

Negatives

• No direct negatives identified; the disposition of 417 shares was for tax liability, a common practice upon vesting of restricted stock.

Industry Context

StockSavvy.ai notes that executive equity grants, such as restricted stock units and stock options, are standard practices in the healthcare industry to align executive incentives with long-term company performance and shareholder value. This filing reflects routine compensation practices for a senior executive at a major health insurer.

Comparison to Industry Standards

• Executive compensation structures involving equity grants are common across large-cap healthcare providers and insurers, similar to practices observed at UnitedHealth Group (UNH) or Cigna Group (CI), where a significant portion of executive pay is tied to company stock performance and vesting schedules.
• The vesting schedule for restricted stock units over three years and stock options exercisable over a decade aligns with typical long-term incentive plans designed to retain talent and encourage sustained growth.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with long-term company performance due to equity grants.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership.

Next Steps

• Restricted share units will vest in three annual installments of 992 shares each, starting March 2, 2027.
• Employee stock options will become exercisable in three annual installments of 3,918 shares each, starting March 2, 2027.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation, including the grant of restricted stock units and stock options, and a disposition of shares for tax purposes. While the increase in insider equity holdings is generally positive for aligning management incentives, these transactions are standard and do not provide new fundamental information to warrant a change in investment recommendation. The company's overall financial health and strategic direction remain the primary drivers for investment decisions.

Keywords

Elevance Health, ELV, Erin Wessling, Insider Trading, Form 4, Restricted Stock Units, Stock Options, Executive Compensation, Beneficial Ownership